A randomized, double-blind, placebo-controlled, stratified, parallel-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 [omigapil] (1.0, 2.5, 7.5 and 15 mg) administered once daily in patients with amyotrophic lateral sclerosis.

Trial Profile

A randomized, double-blind, placebo-controlled, stratified, parallel-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 [omigapil] (1.0, 2.5, 7.5 and 15 mg) administered once daily in patients with amyotrophic lateral sclerosis.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 25 Nov 2011

At a glance

  • Drugs Omigapil (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 25 Nov 2011 Trial status added as 'completed' as reported by ClinicalTrials.gov (Extension: NCT00230074).
    • 25 Nov 2011 Trial status added as 'completed' as reported by ClinicalTrials.gov (Extension: NCT00230074).
    • 25 Nov 2011 Actual patient number (350) added as reported by ClinicalTrials.gov (Extension: NCT00230074).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top